BMS makes a Beeline, bringing 5 assets to biotech’s $300M precision immunology debut
Leading Beeline Medicines’ pipeline is afimetoran, which is in Phase 2 development for systemic lupus erythematosus with data expected later this year.
BMS makes a Beeline, bringing 5 assets to biotech’s $300M precision immunology debut Read More »
